Last reviewed · How we verify

NCT07088718: DUP-SURPASS

Prediction of the SURPASS-CVOT Cardiovascular Outcome Trial in Healthcare Claims Data

Completed Last updated 15 October 2025
What this trial tests

trial testing Tirzepatide in Type 2 Diabetes in 44,671 participants. Completed in 30 July 2025.

Timeline
1 October 2024
Primary endpoint
30 July 2025
30 July 2025

Quick facts

Lead sponsorBrigham and Women's Hospital
StatusCompleted
Study typeOBSERVATIONAL
Enrollment44,671
Start date1 October 2024
Primary completion30 July 2025
Estimated completion30 July 2025
Sites1 location across United States

Drugs / interventions tested

Conditions studied

Sponsor

Brigham and Women's Hospital

Who can join

40 and older, any sex, with Type 2 Diabetes or Major Adverse Cardiac Events. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Investigators are building an empirical evidence base for real world data through large-scale emulation of randomized controlled trials. The investigators' goal is to understand for what types of clinical questions real world data analyses can be conducted with confidence and how to implement such studies.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

  1. Cardiovascular outcomes of semaglutide and tirzepatide for patients with type 2 diabetes in clinical practice.
    Krüger N, Schneeweiss S, Desai RJ, Sreedhara SK, et al · · 2026 · cited 5× · PMID 41207920 · DOI 10.1038/s41591-025-04102-x

Verify or expand the search:

Other trials of Tirzepatide

Trials testing the same drug.

Other recruiting trials for Type 2 Diabetes

Currently open trials in the same condition.

Other Brigham and Women's Hospital trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07088718.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing